Rheumatology Network

Complete Coverage at ACR2014

Must you regretfully miss the event of the year, the American College of Rheumatology annual meeting? Or are you planning to dive into the maelstrom of events at ACR2014? Either way, Rheumatology Network will be there to alert you to the latest and best from the conference. New this year: On-the-spot commentary from Washington DC rheumatologist Paul DeMarco MD.

Recent Content

(ACR2014) In a large prospective study, rheumatoid arthritis patients younger and healthier at baseline were more likely to achieve six-month remission. Choice of drug regimen was also an important factor.

(ACR2014) Salivary gland biopsy, in tandem with clinical signs, may indicate patients with Sjögren's syndrome at greater risk of lymphoma in time to prevent the malignancy or give early treatment.

(ACR2014) Our rheumatologist correspondent found three issues of particular interest: a biomarker test that has gone quickly to market, new diagnostic criteria for gout, and the potential of ultrasound for Sjögren syndrome.

In lupus nephritis, tacrolimus combined with mycophenolate mofetil delivers better remission rates than cyclophosphamide alone.

(ACR2014) A test for 14-3-3-eta, a joint-derived protein that contributes to erosion, proves a powerful aid to diagnosis of rheumatoid arthritis and ankylosing spondylitis, and may also predict response to treatment.

(ACR2014) With FDA approval of the new IL-17A inhibitor expected soon, results of the latest clinical trials presented here show the expected benefits of a first-of-its-kind treatment for axial spondylitis, psoriatic arthritis, and psoriasis.

(ACR2014) To this rheumatologist in attendance, the early announcement of changes to rheumatoid arthritis guidelines -- and some of the changes themselves -- were the big surprise of the American College of Rheumatology annual meeting.

By clicking Accept, you agree to become a member of the UBM Medica Community.